SELLAS Life Sciences Group, Inc.
SLS
$7.68
-$0.30-3.76%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 44.26% | -32.28% | -3.37% | 23.29% | -36.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.60% | -10.76% | -3.36% | -9.81% | -37.14% |
| Operating Income | -52.60% | 10.76% | 3.36% | 9.81% | 37.14% |
| Income Before Tax | -44.62% | -13.67% | 4.46% | 11.63% | 39.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.62% | -13.67% | 4.46% | 11.63% | 39.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.62% | -13.67% | 4.46% | 11.63% | 39.23% |
| EBIT | -52.60% | 10.76% | 3.36% | 9.81% | 37.14% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 26.44% | 40.50% | 39.87% | 48.30% | 68.99% |
| Normalized Basic EPS | 26.33% | 56.19% | 39.78% | 48.27% | 68.97% |
| EPS Diluted | 26.44% | 40.50% | 39.87% | 46.15% | 68.99% |
| Normalized Diluted EPS | 26.33% | 56.19% | 39.78% | 48.27% | 68.97% |
| Average Basic Shares Outstanding | 96.54% | 90.93% | 58.81% | 71.02% | 95.84% |
| Average Diluted Shares Outstanding | 96.54% | 90.93% | 58.81% | 71.02% | 95.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |